168 related articles for article (PubMed ID: 26304825)
1. Improving Pneumococcal Vaccination in Pediatric Rheumatology Patients.
Harris JG; Maletta KI; Ren B; Olson JC
Pediatrics; 2015 Sep; 136(3):e681-6. PubMed ID: 26304825
[TBL] [Abstract][Full Text] [Related]
2. Previsit Planning Improves Pneumococcal Vaccination Rates in Childhood-Onset SLE.
Sivaraman V; Wise KA; Cotton W; Barbar-Smiley F; AlAhmed O; MacDonald D; Lemle S; Yildirim-Toruner C; Ardoin SP; Ardura MI
Pediatrics; 2020 Jan; 145(1):. PubMed ID: 31879277
[TBL] [Abstract][Full Text] [Related]
3. Prevention of pneumococcal disease among infants and children - use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine - recommendations of the Advisory Committee on Immunization Practices (ACIP).
Nuorti JP; Whitney CG;
MMWR Recomm Rep; 2010 Dec; 59(RR-11):1-18. PubMed ID: 21150868
[TBL] [Abstract][Full Text] [Related]
4. Improving the Combination Pneumococcal Vaccination Rate in Systemic Lupus Erythematosus Patients at an Adult Rheumatology Practice.
Garg S; Tsagaris K; Cozmuta R; Lipson A
J Rheumatol; 2018 Dec; 45(12):1656-1662. PubMed ID: 30173154
[TBL] [Abstract][Full Text] [Related]
5. Preventing pneumococcal disease among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP).
Advisory Committee on Immunization Practices
MMWR Recomm Rep; 2000 Oct; 49(RR-9):1-35. PubMed ID: 11055835
[TBL] [Abstract][Full Text] [Related]
6. Immunogenicity of 23-Valent Pneumococcal Vaccine in Children with Systemic Lupus Erythematosus.
Alyasin S; Adab M; Hosseinpour A; Amin R; Babaei M
Iran J Immunol; 2016 Sep; 13(3):204-19. PubMed ID: 27671512
[TBL] [Abstract][Full Text] [Related]
7. Experience with pneumococcal polysaccharide conjugate vaccine (conjugated to CRM197 carrier protein) in children and adults.
Durando P; Faust SN; Fletcher M; Krizova P; Torres A; Welte T
Clin Microbiol Infect; 2013 Oct; 19 Suppl 1():1-9. PubMed ID: 24083785
[TBL] [Abstract][Full Text] [Related]
8. Using medical record reminders to improve pneumococcal vaccination rates.
Warner EA; Seleznick MJ
Jt Comm J Qual Saf; 2004 Jun; 30(6):331-4. PubMed ID: 15208982
[TBL] [Abstract][Full Text] [Related]
9. Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine.
Lexau CA; Lynfield R; Danila R; Pilishvili T; Facklam R; Farley MM; Harrison LH; Schaffner W; Reingold A; Bennett NM; Hadler J; Cieslak PR; Whitney CG;
JAMA; 2005 Oct; 294(16):2043-51. PubMed ID: 16249418
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of conjugate pneumococcal vaccination in Singapore: comparing estimates for 7-valent, 10-valent, and 13-valent vaccines.
Tyo KR; Rosen MM; Zeng W; Yap M; Pwee KH; Ang LW; Shepard DS
Vaccine; 2011 Sep; 29(38):6686-94. PubMed ID: 21745516
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of the 7-valent pneumococcal conjugate vaccine in children with sickle cell disease in the first decade of life.
Adamkiewicz TV; Silk BJ; Howgate J; Baughman W; Strayhorn G; Sullivan K; Farley MM
Pediatrics; 2008 Mar; 121(3):562-9. PubMed ID: 18310206
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of a 10- versus 13-valent pneumococcal conjugate vaccine in Denmark and Sweden.
Klok RM; Lindkvist RM; Ekelund M; Farkouh RA; Strutton DR
Clin Ther; 2013 Feb; 35(2):119-34. PubMed ID: 23312274
[TBL] [Abstract][Full Text] [Related]
13. Pneumococcal vaccination programs and the burden of invasive pneumococcal disease in Ontario, Canada, 1995-2011.
Rudnick W; Liu Z; Shigayeva A; Low DE; Green K; Plevneshi A; Devlin R; Downey J; Katz K; Kitai I; Krajden S; Ostrowska K; Richardson D; Richardson S; Sarabia A; Silverman M; Simor AE; Tyrrell G; McGeer A;
Vaccine; 2013 Dec; 31(49):5863-71. PubMed ID: 24099873
[TBL] [Abstract][Full Text] [Related]
14. Eight years of active proposal of pneumococcal 23-valent polysaccharide vaccine: survey on coverage rate among elderly and chronic patients.
Martinelli D; Tafuri S; Caputi G; Fortunato F; Reggio P; Germinario C; Prato R
Am J Infect Control; 2010 May; 38(4):e8-e15. PubMed ID: 20211508
[TBL] [Abstract][Full Text] [Related]
15. Recurrent invasive pneumococcal disease in children--host factors and vaccination response.
Ingels HA
Dan Med J; 2015 Jul; 62(7):. PubMed ID: 26183055
[TBL] [Abstract][Full Text] [Related]
16. Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease--United States, 1998-2003.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2005 Sep; 54(36):893-7. PubMed ID: 16163262
[TBL] [Abstract][Full Text] [Related]
17. Pharmacists as providers: targeting pneumococcal vaccinations to high risk populations.
Taitel M; Cohen E; Duncan I; Pegus C
Vaccine; 2011 Oct; 29(45):8073-6. PubMed ID: 21864625
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of administering 13-valent pneumococcal conjugate vaccine in addition to 23-valent pneumococcal polysaccharide vaccine to adults with immunocompromising conditions.
Cho BH; Stoecker C; Link-Gelles R; Moore MR
Vaccine; 2013 Dec; 31(50):6011-21. PubMed ID: 24148572
[TBL] [Abstract][Full Text] [Related]
19. Vaccination, underlying comorbidities, and risk of invasive pneumococcal disease.
Yildirim I; Shea KM; Little BA; Silverio AL; Pelton SI;
Pediatrics; 2015 Mar; 135(3):495-503. PubMed ID: 25647674
[TBL] [Abstract][Full Text] [Related]
20. Changing epidemiology of invasive pneumococcal disease among White Mountain Apache persons in the era of the pneumococcal conjugate vaccine.
Lacapa R; Bliss SJ; Larzelere-Hinton F; Eagle KJ; McGinty DJ; Parkinson AJ; Santosham M; Craig MJ; O'Brien KL
Clin Infect Dis; 2008 Aug; 47(4):476-84. PubMed ID: 18627249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
